Advertisement

Breast cancer in transgender patients: A systematic review. Part 1: Male to female

      Abstract

      Male-to-Female (MtF) breast cancer events have been reported since 1968 however, MtF patients' risk of breast cancer remain unclear. Following PRISMA guidelines, electronic databases and grey literature were searched April 2018 to identify breast cancer events in MtF transgender persons. Screening and data extraction were independently performed in duplicate by two reviewers. Study quality was assessed using a component-based system. Qualitative analysis was performed on study characteristics, patient demographics, breast cancer characteristics, and breast cancer presentation and management. Eighteen articles met inclusion criteria representing 22 breast cancer events. Median age at breast cancer diagnosis was 51.5 years. The most common breast cancer type was adenocarcinomas (59.1%) and half of the breast cancers were hormone sensitive, with estrogen receptor positive status in 10 of 19 tested and progesterone receptor positive status in 5 of 14 tested. The most common presentation was breast lump (n = 6, 42.9%), two patients had palpable lymph nodes at presentation (14.3%), and six patients eventually developed metastases (42.9%). Seven patients had a recorded positive breast cancer family history and one was BRCA2 positive. Breast cancers were treated with mastectomies (simple, modified radical, and radical), wide local excision, lumpectomy, or were unclear. Four patients received hormone therapy (23.5%), two received radiation (11.8%), and seven received chemotherapy (41.2%). Breast cancer is present in MtF patients and commonly presents at a younger age with a palpable mass. Major gaps in the literature include lack of transgender population data and long term follow-up. This work highlights the need for screening recommendations.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Surgical Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Koh J.
        The history of the concept of gender identity disorder.
        Seishin Shinkeigaku Zasshi. 2012; 114 ([Article in Japanese]): 673-680
        • Collin L.
        • Reisner S.L.
        • Tangpricha V.
        • Goodman M.
        Prevalence of transgender depends on the “case” definition: a systematic review.
        J Sex Med. 2016; 13: 613-626
        • Dhejne C.
        • Öberg K.
        • Arver S.
        • Landén M.
        An analysis of all applications for sex reassignment surgery in Sweden, 1960–2010: prevalence, incidence, and regrets.
        Arch Sex Behav. 2014; 43: 1535-1545
        • Roberts T.K.
        • Fantz C.R.
        Barriers to quality health care for the transgender population.
        Clin Biochem. 2014; 47: 983-987
        • Symmers W.C.
        Carcinoma of the breast in trans-sexual individuals after surgical and hormonal interference with the primary and secondary sex characteristics.
        Br Med J. 1968; 2: 83-85
        • Gooren L.J.
        • van Trotsenburg M.A.
        • Giltay E.J.
        • van Diest P.J.
        Breast cancer development in transsexual subjects receiving cross-sex hormone treatment.
        J Sex Med. 2013; 12: 3129-3134
        • Brown G.R.
        • Jones K.T.
        Incidence of breast cancer in a cohort of 5135 transgender veterans.
        Breast Cancer Res Treat. 2015; 149: 191-198
        • Zucker K.J.
        • Lawrence A.A.
        Epidemiology of gender identity disorder: recommendations for the standards of care of the world professional association for transgender health.
        Int J Transgenderism. 2009; 11: 8-18
        • Blosnich J.
        • Brown G.
        • Shipherd J.
        • Kauth M.
        • Piegari R.
        • Bossarte R.
        Prevalence of gender identity disorder and suicide risk among transgender veterans utilizing veterans health administration care.
        Am J Public Health. 2013; 103: e27-e32
        • Moher D.
        • Liberati A.
        • Tetzlaff J.
        • Altman D.
        • The PRISMA Group
        Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement.
        PLoS Med. 2009; 6e1000097
        • Altman D.G.
        Systematic reviews of evaluations of prognostic variables.
        Br Med J. 2001; 323: 224-228
        • Laupacis A.
        • Wells G.
        • Richardson W.S.
        • Tugwell P.
        • Evidence-Based Medicine Working Group
        Users' guides to the medical literature. V. How to use an article about prognosis.
        J Am Med Assoc. 1994; 272: 234-237
        • Pritchard T.J.
        • Pankowsky D.A.
        • Crowe J.P.
        • Abdul-Karim F.W.
        Breast cancer in a male-to-female transsexual: a case report.
        J Am Med Assoc. 1988; 259: 2278-2280
        • Ganly I.
        • Taylor E.W.
        Breast cancer in a trans-sexual man receiving hormone replacement therapy.
        Br J Surg. 1995; 82: 341
        • Kanhai R.C.J.
        • Hage J.J.
        • Bloemena E.
        • Van Diest P.J.
        • Karim R.B.
        Mammary fibroadenoma in a male-to-female transsexual.
        Histopathology. 1999; 35: 183-185https://doi.org/10.1046/j.1365-2559
        • Grabellus F.
        • Worm K.
        • Willruth A.
        • Schmitz K.J.
        • Otterbach F.
        • Baba H.A.
        • et al.
        ETV6-NTRK3 gene fusion in a secretory carcinoma of the breast of a male-to-female transsexual.
        Breast. 2005; 20: 71-74
        • Kelley K.
        Breast cancer in a transgender patient and role for screening mammography.
        2006 (Society of General Internal Medicine, Clinical Vignetter. 1/06)
        http://www.apconline.org
        Date accessed: August 1, 2015
        • Kuroda H.
        • Ohnisi K.
        • Sakamoto G.
        • Itoyama S.
        Clinicopathological study of breast tissue in female-to-male transsexuals.
        Surg Today. 2008; 38: 1067-1071
        • Dhand A.
        • Dhaliwal G.
        Examining patient conceptions: a case of metastatic breast cancer in an African American male to female transgender patient.
        J Gen Intern Med. 2010; 25: 158-161
        • Weyers S.
        • Villeirs G.
        • Vanherreweghe E.
        • Verstraelen H.
        • Monstrey S.
        • Van den Broecke R.
        • et al.
        Mammography and breast sonography in trans-sexual women.
        Eur J Radiol. 2010; 74: 508-513
        • Asscheman H.
        • Giltay E.J.
        • Megens J.A.J.
        • de Ronde W.P.
        • van Trotsenburg M.A.
        • Gooren L.J.
        A long-term follow-up study of mortality in transsexuals receiving treatment with cross-sex hormones.
        Eur J Endocrinol. 2011; 164: 635-642
        • Pattison T.
        • McLaren R.
        Triple negative breast cancer in a male-to-female transsexual.
        Intern Med J. 2013; 43: 203-205
        • Maglione K.D.
        • Margolies L.
        • Jaffer S.
        • Szabo J.
        • Schmidt H.
        • Weltz C.
        • et al.
        Breast cancer in male-to-female transsexuals: use of breast imaging for detection.
        AJR Am J Roentgenol. 2014; 203: 735-740https://doi.org/10.2214/AJR.14.12723
        • Sattari M.
        Breast cancer in male-to-female transgender patients: a case for caution.
        Clin Breast Cancer. 2015; 15: 67-69
        • Orofino N.
        • Guidotti F.
        • Cattaneo D.
        • Sciumè M.
        • Gianelli U.
        • Cortelezzi A.
        • et al.
        Marked eosinophilia as initial presentation of breast implant-associated anaplastic large cell lymphoma.
        Leuk Lymphoma. 2016; 57: 2712-2715
        • de Boer M.
        • van der Sluis W.B.
        • de Boer J.P.
        • Overbeek L.I.H.
        • van Leeuwen F.E.
        • Rakhorst H.A.
        • et al.
        Breast implant-associated anaplastic large-cell lymphoma in a transgender woman.
        Aesthetic Surg J. 2017; 37: NP83-NP87
        • Patzelt M.
        • Zarubova L.
        • Klener P.
        • Barta J.
        • Benkova K.
        • Brandejsova A.
        • et al.
        Anaplastic large-cell lymphoma associated with breast implants: a case report of a transgender female.
        Aesthetic Plast Surg. 2018; 42: 451-455
        • Gondusky C.J.
        • Kim M.J.
        • Kalantari B.N.
        • Khalkhali I.
        • Dauphine C.
        Examining the role of screening mammography in men at moderate risk for breast cancer: two illustrative cases.
        Breast J. 2015; 21: 316-317
        • Teoh Z.H.
        • Archampong D.
        • Gate T.
        Breast cancer in male-to-female (MtF) transgender patients: is hormone receptor negativity a feature?.
        BMJ Case Rep. 2015; 2015: 201
        • Corman V.
        • Potorac I.
        • Manto F.
        • Dassy S.
        • Segers K.
        • Thiry A.
        • et al.
        Breast cancer in a male to female transsexual patient with a BRCA2 mutation.
        Endocr Relat Cancer. 2016; 23: 391-397
        • The Canadian task force on preventive health care
        Recommendations on screening for breast cancer in average-risk women aged 40-74 years.
        CMAJ. 2011; 183: 1991-2001
      1. Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, et al.(eds). SEER cancer statistics review, 1975-2015. Bethesda, MD: National Cancer Institute; 2018 https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site.

        • Oeffinger K.C.
        • Fontham E.T.
        • Etzioni R.
        • Herzig A.
        • Michaelson J.
        • Shih Y.C.
        • et al.
        Breast cancer screening for women at average risk: 2015 guideline update from the American Cancer Society.
        J Am Med Assoc. 2015; 314: 1599-1614
        • Deutsch M.B.
        Guidelines for the primary and gender-affirming care of transgender and gender non-binary people.
        (Center of Excellence for Transgender Health)2nd ed. Department of Family & Community Medicine. University of California, San FranciscoJuly 2017 ([Published])
        • U.S. Food & Drug
        Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).
        2018
        • Burcombe R.J.
        • Makris A.
        • Pittam M.
        • Finer N.
        Breast cancer after bilateral subcutaneous mastectomy in a female-to-male trans-sexual.
        Breast. 2003; 12: 290-293
        • Russo J.
        • Russo I.H.
        The role of estrogen in the initiation of breast cancer.
        J Steroid Biochem Mol Biol. 2006; 102: 89-96
        • Wierckx K.
        • Mueller S.
        • Weyers S.
        • Van Caenegem E.
        • Roef G.
        • Heylens G.
        • et al.
        Long-term evaluation of cross-sex hormone treatment in transsexual persons.
        J Sex Med. 2012; 9: 2641-2651
        • Rossouw J.E.
        • Anderson G.L.
        • Prentice R.L.
        • LaCroix A.Z.
        • Kooperberg C.
        • Stefanick M.L.
        • et al.
        • Writing Group for the Women's Health Initiative Investigators
        Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial.
        J Am Med Assoc. 2002; 288: 321-333
        • van Kesteren P.J.
        • Asscheman H.
        • Megens J.A.
        • Gooren L.J.
        Mortality and morbidity in transsexual subjects treated with cross-sex hormones.
        Clin Endocrinol (Oxf). 1997; 47: 337-342
        • Canadian Cancer Society
        Screening in LGBTQ communities.
        Canadian Cancer Society. 2018; ([Accessed July 30])
        • Hembree W.C.
        • Cohen-Kettenis P.
        • Delemarre-van de Waal H.A.
        • Gooren L.
        • Meyer III, W.
        • Spack N.
        • et al.
        Endocrine treatment of transsexual persons:an endocrine society clinical practice guideline.
        J Clin Endocrinol Metab. 2009; 94: 3132-3154
        • Williamson C.
        Providing care to transgender persons: a clinical approach to primary care, hormones, and HIV management.
        J Assoc Nurses AIDS Care. 2010; 21: 221-229
        • Snelgrove J.
        • Jasudavisius A..
        • Rowe B.
        • Head E.
        • Bauer G.
        “Completely out-at-sea” with “two-gender medicine”: a qualitative analysis of physician-side barriers to providing healthcare for transgender patients.
        BMC Health Serv Res. 2012; 12: 110
        • Tang S.S.K.
        • Gui G.P.H.
        A review of the oncologic and surgical management of breast cancer in the augmented breast: diagnostic, surgical and surveillance challenges.
        Ann Surg Oncol. 2011; 18: 2173-2181
        • Weyers S.
        • Elaut E.
        • De Sutter P.
        • Gerris J.
        • T'Sjoen G.
        • Heylens G.
        • et al.
        Long-term assessment of the physical, mental, and sexual health among transsexual women.
        J Sex Med. 2009; 6: 752-760
        • Gooren L.
        Care of transsexual persons.
        N Engl J Med. 2011; 364: 1251-1257

      Linked Article

      • Breast cancer in transgender patients: A systematic review. Part 2: Female to Male
        European Journal of Surgical OncologyVol. 44Issue 10
        • Preview
          Transgender men or Female-to-Male (FtM) patients' risk of breast cancer and screening recommendations remain unclear. The objective of this study is to perform a systematic review of the literature and document all reported cases of FtM breast cancer as well as provide research recommendations. Following PRISMA guidelines, MEDLINE, ProQuest, PubMed, and Cochrane Database of Systematic Reviews were searched from inception until September 15, 2016. Screening and data extraction were performed in duplicate by two independent reviewers (RH and JS).
        • Full-Text
        • PDF